| Bioactivity | CLX-0921 is an orally active PPARγ agonist with an IC50 of 1.54 μM. CLX-0921 has a potent antihyperglycemic activity, and can be used for the study of type 2 diabetes[1]. |
| Invitro | CLX-0921（0.01 M、0.1 M、1.0 M 和 10 M）可增加 3T3-L1 脂肪细胞的葡萄糖摄取。CLX-0921 具有强效的抗高血糖活性，且脂肪形成潜力低[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. 0 --> CLX-0921 相关抗体: |
| In Vivo | CLX-0921（3.1-12.5 mg/kg；口服管饲；每日一次；持续 19 天）表现出剂量依赖性的抗高血糖活性[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: |
| CAS | 249886-47-3 |
| Formula | C28H25NO7S |
| Molar Mass | 519.57 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Debendranath Dey, et al. A novel peroxisome proliferator-activated gamma (PPAR gamma) agonist, CLX-0921, has potent antihyperglycemic activity with low adipogenic potential. Metabolism. 2003 Aug;52(8):1012-8. |